ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity

Frontiers in Pharmacology

Volumn 4 NOV, Issue , 2013, Pages

  Gauthier, Charlotte ^a   Ozvegy Laczka, Csilla ^b   Szakacs, Gergely ^b   Sarkadi, Balazs ^c   Pietro, Attilio Di ^a  

^a CNRS   (France)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

breast cancer resistance protein ABCG2; Collateral sensitivity; Glutathione efflux; Intracellular glutathione depletion; Modulators; Multidrug resistance protein ABCC1; Selective apoptosis

Indexed keywords

2',5' DIHYDROXYCHALCONE; 6 PRENYLCHRYSIN; ADENOSINE TRIPHOSPHATASE; BREAST CANCER RESISTANCE PROTEIN; CHALCONE DERIVATIVE; GLUTATHIONE; METHOTREXATE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; UNCLASSIFIED DRUG; VERAPAMIL; XANTHONE DERIVATIVE;

ANIMAL CELL; ARTICLE; CATALYSIS; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; DRUG TRANSPORT; EMBRYO; ENZYME ACTIVITY; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; INSECT CELL; MEMBRANE VESICLE; NONHUMAN; PROTEIN EXPRESSION;

EID: 84889665595     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00138     Document Type: Article

References (60)

1. Ahmed-Belkacem, A., Pozza, A., Munoz-Martinez, F., Bates, S. E., Castanys, S., Gamarro, F., et al. (2005). Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res. 65, 4852-4860. doi: 10.1158/0008-5472.CAN-04-1817
2. Allen, J. D., van Loevezijn, A., Lakhai, J. M., van der Valk, M., van Tellingen, O., Reid, G., et al. (2002). Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 1, 417-425.
3. Allikmets, R., Schriml, L. M., Hutchinson, A., Romano-Spica, V., and Dean, M. (1998). A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58, 5337-5339.
4. Anderson, M. E. (1985). Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol. 113, 548-555. doi: 10.1016/S0076-6879(85)13073-9
5. Bakos, E., Hegedüs, T., Hollo, Z., Welker, E., Tusnàdy, G. E., Zaman, G. F., et al. (1996). Membrane topology and glycosylation of the human multidrug resistance-associated protein. J. Biol. Chem. 271, 12322-12326. doi: 10.1074/jbc.271.21.12322
6. Barattin, R., Perrotton, T., Trompier, D., Lorendeau, D., Di Pietro, A., du Moulinet d'Hardemare, A., et al. (2010). Iodination of verapamil for a stronger induction of death, through GSH efflux, of cancer cells overexpressing MRP1. Bioorg. Med. Chem. 18, 6265-6274. doi: 10.1016/j.bmc.2010.07.031
7. Battacharya, S., Das, A., Mallya, K., and Ahmad, I. (2007). Maintenance of retinal stem cells by Abcg2 is regulated by notch signaling. J. Cell Sci. 120(Pt 15), 2652-2662. doi: 10.1242/jcs.008417
8. Brechbuhl, H. M., Gould, N., Kachadourian, R., Riekhof, W. R., Voelker, D. R., and Day, B. J. (2010). Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2. J. Biol. Chem. 285, 16582-16587. doi: 10.1074/jbc.M109.090506
9. Brechbuhl, H. M., Min, E., Kariya, C., Frederick, B., Raben, D., and Day, B. J. (2009). Select cyclopentenone prostaglandins trigger glutathione efflux and the role of ABCG2 transport. Free Radic. Biol. Med. 47, 722-730. doi: 10.1016/j.freeradbiomed.2009.06.005
10. Chen, Q., Li, W., Wan, Y., Xia, X., Wu, Q., Chen, Y., et al. (2012). Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways. Hepatology 55, 1820-1829. doi: 10.1002/hep.25549
11. Chen, Z. S., Robey, R. W., Belinsky, M. G., Shchaveleva, I., Ren, X. Q., Sugimoto, Y., et al. (2003). Transport of methotrexate, methotrexate polyglutamates and 17 beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 63, 4048-4054.
12. Cole, S. P., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., et al. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650-1654. doi: 10.1126/science.1360704
13. Cripe, L. D., Uno, H., Paietta, E. M., Litzow, M. R., Ketterling, R. P., Bennett, J. M., et al. (2010). Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 116, 4077-4085. doi: 10.1182/blood-2010-04-277269
14. Cui, X. Y., Skretting, G., Jing, Y., Sun, H., Sandset, P. M., and Sun, L. (2013). Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells. Blood Cells Mol. Dis. 51, 177-184. doi: 10.1016/j.bcmd.2013.05.003
15. de Boussac, H., Orban, T. I., Varady, G., Tihanyi, B., Bacquet, C., Brozik, A., et al. (2012). Stimulus-induced expression of the ABCG2 multidrug transporter in HepG2 hepatocarcinoma model cells involves the ERK1/2 cascade and alternative promoters. Biochem. Biophys. Res. Commun. 426, 172-176. doi: 10.1016/j.bbrc.2012.08.046
16. Deeken, J. F., Robey, R. W., Shukla, S., Steadman, K., Chakraborty, A. R., Poonkuzhali, B., et al. (2009). Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. Mol. Pharmacol. 76, 946-956. doi: 10.1124/mol.109.056192
17. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., et al. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95, 15665-15670. doi: 10.1073/pnas.95.26.15665
18. Dubrovska, A., Hartung, A., Bouchez, L. C., Walker, J. R., Reddy, V. A., Cho, C. Y., et al. (2012). CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signaling. Br. J. Cancer 107, 43-52. doi: 10.1038/bjc.2012.105
19. Genoux-Bastide, E., Lorendeau, D., Nicolle, E., Yahiaoui, S., Magnard, S., Di Pietro, A., et al. (2011). Identification of xanthones as selective killers of cancer cells overexpressing the ABC transporter MRP1. ChemMedChem 6, 1478-1484. doi: 10.1002/cmdc.201100102
20. Gilani, R. A., Kazi, A. A., Shah, P., Schech, A. J., Chumsri, S., Sabnis, G., et al. (2012). The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res. Treat. 135, 681-692. doi: 10.1007/s10549-012-2148-8
21. Goler-Baron, V., and Assaraf, Y. G. (2012). Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics. PLoS ONE 7:e35487. doi: 10.1371/journal.pone.0035487
22. Hall, M. D., Handley, M. D., and Gottesman, M. M. (2009). Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol. Sci. 30, 546-556. doi: 10.1016/j.tips.2009.07.003
23. Hessel, S., and Lampen, A. (2010). All-trans retinoic acid enhances the transport of phase II metabolites of benzo[a]pyrene by inducing the breast cancer resistance protein expression in Caco-2 cells. Toxicol. Lett. 197, 151-155. doi: 10.1016/j.toxlet.2010.05.018
24. Hong, Y. B., Kang, H. J., Kwon, S. Y., Kim, H. J., Kwon, K. Y., Cho, C. H., et al. (2010). Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells. Pancreas 39, 463-472. doi: 10.1097/MPA.0b013e3181c31314
25. Honjo, Y., Hrycyna, C. A., Yan, Q. W., Medina-Perez, W. Y., Robey, R. W., van de Laar, A., et al. (2001). Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 61, 6635-6639.
26. Ishikawa, T., Kajimoto, Y., Sun, W., Nakagawa, H., Inoue, Y., Ikegami, Y., et al. (2013). Role of Nrf2 in cancer photodynamic therapy: regulation of human ABC transporter ABCG2. J. Pharm. Sci. 102, 3058-3069. doi: 10.1002/jps.25563
27. Ito, M., Kajino, K., Abe, M., Fujimura, T., Mineki, R., Ikegami, T., et al. (2013). NP-1250, an ABCG2 inhibitor, induces apoptotic cell death in mitoxantrone-resistant breast carcinoma MCF7 cells via a caspase-independent pathway. Oncol. Rep. 29, 1492-1500. doi: 10.3892/or.2013.2249
28. Juliano, R. L., and Ling, V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152-162. doi: 10.1016/0005-2736(76)90160-7
29. Katoh, M., and Katoh, M. (2010). Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int. J. Oncol. 36, 415-420. doi: 10.3892/ijo_00000514
30. Keppler, D., Leier, I., and Jedlitschky, G. (1997). Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol. Chem. 378, 787-791.
31. Kolitz, J. E., George, S. L., Marcucci, G., Vij, R., Powell, B. L., Allen, S. L., et al. (2010). P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: cancer and leukemia group B study 19808. Blood 116, 1413-1421. doi: 10.1182/blood-2009-07-229492
32. Leier, I., Jedlitschki, G., Buchholz, U., Cole, S. P., Deeley, R. G., and Keppler, D. (1994). The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 269, 27807-27810.
33. Li, H., Gao, Q., Guo, L., and Lu, S. H. (2011). The PTEN/P13K/AKT pathway regulates stem-like cells in primary esophageal carcinoma cells. Cancer Biol. Ther. 11, 950-958. doi: 10.4161/cbt.11.11.15531
34. Ludwig, J. A., Szakács, G., Martin, S. E., Chu, B. F., Cardarelli, C., Sauna, Z. E., et al. (2006). Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res. 66, 4808-4815. doi: 10.1158/0008-5472.CAN-05-3322
35. Miyake, K., Mickley, L., Litman, T., Zhan, Z., Robey, R., Cristensen, B., et al. (1999). Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59, 8-13.
36. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63. doi: 10.1016/0022-1759(83)90303-4
37. Nakanishi, T., and Ross, D. D. (2012). Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin. J. Cancer 31, 73-99. doi: 10.5732/cjc.011.10320
38. Ozvegy, C., Litman, T., Szakacs, G., Nagy, Z., Bates, S. E., Varadi, A., et al. (2001). Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem. Biophys. Res. Commun. 285, 111-117. doi: 10.1006/bbrc.2001.5130
39. Ozvegy-Laczka, C., Köblös, G., Sarkadi, B., and Varadi, A. (2005). Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. Biochim. Biophys. Acta 1668, 53-63. doi: 10.1016/j.bbamem.2004.11.005
40. Perrotton, T., Trompier, D., Chang, X-B., Di Pietro, A., and Baubichon-Cortay, H. (2007). S- and R-verapamil differentially modulate the multidrug resistance protein MRP1. J. Biol. Chem. 282, 31542-31548. doi: 10.1074/jbc.M703964200
41. Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R., and Gottesman, M. M. (2012). Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat. 15, 98-105. doi: 10.1016/j.drup.2012.03.002
42. Robey, R. W., Honjo, Y., Morisaki, K., Nadjem, T. A., Runge, S., Risbood, M., et al. (2003). Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer 89, 1971-1978. doi: 10.1038/sj.bjc.6601370
43. Robey, R. W., Massey, P. R., Amiri-Kordestani, L., and Bates, S. E. (2010). ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med. Chem. 10, 625-633. doi: 10.2174/187152010794473957
44. Shelton, P., and Jaiswal, A. K. (2013). The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene? FASEB J. 27, 414-423. doi: 10.1096/fj.12-217257
45. Shen, S., Callaghan, D., Juzwik, C., Xiong, H., Huang, P., and Zhang, W. (2010). ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer's disease. J. Neurochem. 114, 1590-1604. doi: 10.1111/j.1471-4159.2010.06887.x
46. Singh, A., Wu, H., Zhang, P., Happel, C., Ma., J., and Biswal, S. (2010). Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol. Cancer Ther. 9, 2365-2376. doi: 10.1158/1535-7163.MCT-10-0108
47. Singh, R. R., Kunkalla, K., Qu, C., Schlette, E., Neelapu, S. S., Samaniego, F., et al. (2011). Abcg2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 30, 4874-4886. doi: 10.1038/onc.2011.195
48. Suzuki, M., Suzuki, H., Sugimoto, Y., and Sugiyama, Y. (2003). ABCG2 transports sulfated conjugates of steroids and xenobiotics. J. Biol. Chem. 278, 22644-22649. doi: 10.1074/jbc.M212399200
49. Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., and Gottesman, M. M. (2006). Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219-234. doi: 10.1038/nrd1984
50. Szakács, G., Varadi, A., Ozvegy-Laczka, C., and Sarkadi, B. (2008). The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-tox). Drug Discov. Today 13, 379-393. doi: 10.1016/j.drudis.2007.12.010
51. Telbisz, A., Hegedus, C., Ozvegy-Laczka, C., Goda, K., Varady, G., Takats, Z., et al. (2012). Antibody binding shift assay for rapid screening of drug interactions with the human ABCG2 multidrug transporter. Eur. J. Pharm. Sci. 45, 101-109. doi: 10.1016/j.ejps.2011.10.021
52. Telbisz, A., Müller, M., Ozvegy-Laczka, C., Homolya, L., Szente, L., Varadi, A., et al. (2007). Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochim. Biophys. Acta 1768, 2698-2713. doi: 10.1016/j.bbamem.2007.06.026
53. Tietze, F. (1969). Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem. 27, 502-522. doi: 10.1016/0003-2697(69)90064-5
54. Trompier, D., Chang, X. B., Barattin, R., du Moulinet d'Hardemare, A., Di Pietro, A., and Baubichon-Cortay, H. (2004). Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res. 64, 4950-4956. doi: 10.1158/0008-5472.CAN-04-0143
55. Türk, D., Hall, M. D., Chu, B. F., Ludwig, J. A., Fales, H. M., Gottesman, M. M., et al. (2009). Identification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res. 69, 8293-8301. doi: 10.1158/0008-5472.CAN-09-2422
56. Usongo, M., and Farookhi, R. (2012). β-Catenin/Tcf-signaling appears to establish the murine ovarian surface epithelium (OSE) and remains active in selected postnatal OSE cells. BMC Dev. Biol. 12:17. doi: 10.1186/1471-213X-12-17
57. Valdameri, G., Gauthier, C., Terreux, R., Kachadourian, R., Day, B. J., Winnischofer, S. M., et al. (2012). Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity. J. Med. Chem. 55, 3193-3200. doi: 10.1021/jm2016528
58. Wang, X. Q., Ongkeko, W. M., Chen, L., Yang, Z. F., Lu, P., Chen, K. K., et al. (2010). Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology 52, 528-539. doi: 10.1002/hep.23692
59. Zhang, M., Mathur, A., Zhang, Y., Xi, S., Atay, S., Hong, J. A., et al. (2012). Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells. Cancer Res. 72, 4178-4192. doi: 10.1158/0008-5472.CAN-11-3983
60. Zhu, M. M., Tong, J. L., Xu, Q., Nie, F., Xu, X. T., Xia, S. D., et al. (2012). Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer. PLoS ONE 7:e41763. doi: 10.1371/journal.pone.0041763